{"url_path":"/sec/stok/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-289409-index.html","accession_number":"0001193125-26-289409","cik":"0001623526","ticker":"STOK","issuer_name":"Stoke Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-289409-index.html","primary_entity_key":"0001623526","primary_entity_name":"Stoke Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD.\n\nOn June 30, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The Company is furnishing a copy of the Press Release, which is attached hereto as Exhibit 99.1.\n\nThe information furnished with this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing."}